Discovering Potential Drug Targets for Cervical and Vulvar Cancers: IGHV3-21

Target Name: IGHV3-21

NCBI ID: G28444

IGHV3-21

Other Name(s): IGHV321 | Immunoglobulin heavy variable 3-21 | VH | immunoglobulin heavy variable 3-21

Discovering Potential Drug Targets for Cervical and Vulvar Cancers: IGHV3-21

IGHV3-21 (IGHV321) is a human papillomavirus (HPV) type 16 (HPV16) viral load protein that is expressed in the majority of cervical and vulvar squamous epithelial tissue. It is also expressed in the normal epithelial tissue of the vulvar area, including the urethra and the cervix. IGHV3-21 has been identified as a potential drug target (DM) for cervical and vulvar cancers, due to its expression in these cancer tissues and its potential to enhance the sensitivity of cancer cells to.

IGHV3-21 is a transmembrane protein that is expressed in the cytoplasm of human keratinocytes, including those of the vulvar and cervical regions. It is composed of a cytoplasmic tail and a transmembrane region that contains a cytoplasmic domain and a transmembrane domain. of IGHV3-21 consists of a variable region that is involved in its cell surface localization and interactions with other cellular components. The transmembrane region of IGHV3-21 contains a large extracellular domain (ECD) that is involved in its interaction with various cellular signaling pathways , including the TGF-β pathway.

IGHV3-21 has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and cell-cell adhesion. It has been shown to play a role in the development and progression of cervical and vulvar cancers, by promoting the growth and survival of cancer cells and by inhibiting the immune response to cancer cells.

One of the key mechanisms by which IGHV3-21 promotes cancer cell growth and survival is its role in the TGF-β pathway. The TGF-β pathway is a complex signaling pathway that is involved in the regulation of cellular growth, differentiation, and inflammation . IGHV3-21 has been shown to be a positive regulator of the TGF-β pathway, by increasing the levels of transforming growth factor-尾1 (TGF-β1) in cancer cells and by inhibiting the negative regulatory effects of TGF-β1 on cancer. cell growth.

Another mechanism by which IGHV3-21 promotes cancer cell survival is its role in cell-cell adhesion. IGHV3-21 has been shown to be involved in the regulation of cell-cell adhesion by interacting with the cadherin protein, which is a transmembrane protein that is involved in cell-cell adhesion. IGHV3-21 has been shown to enhance the adhesion of cancer cells to the extracellular matrix, by increasing the levels of cadherin in cancer cells and by inhibiting the negative effects of cadherin on cell-cell adhesion.

IGHV3-21 has also been shown to promote cancer cell apoptosis, which is the process by which cancer cells undergo programmed cell death. IGHV3-21 has also been shown to induce apoptosis in cancer cells, by activating several apoptosis-related genes, including Bcl- 2 and p53. These genes are involved in the regulation of cell cycle, DNA damage repair, and cell apoptosis, and are commonly disrupted in cancer cells.

In conclusion, IGHV3-21 is a promising drug target (DM) for cervical and vulvar cancers. Its expression in the majority of cervical and vulvar squamous epithelial tissue and its potential involvement in the TGF-β pathway and cell-cell adhesion make it a promising target for cancer chemotherapy. Additionally, IGHV3-21 has also been shown to promote apoptosis in cancer cells, which may be a potential mechanism for its anti-cancer properties. Further studies are needed to fully understand the role of IGHV3-21 in cancer and to develop effective treatments.

Protein Name: Immunoglobulin Heavy Variable 3-21

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV3-21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets